Navigation Links
B-Cell Biologic Therapy Could Revolutionize Rheumatoid Arthritis Treatment

Biologic therapy directed at B-cells could turn out be more effective in the treatment of rheumatoid arthritis, a chronic inflammatory disease arising out of an auto immune disorder.//

An international study conducted on Rituximab, a form of biologic therapy for treatment of rheumatoid arthritis has been found to achieve remission in rheumatoid arthritis patients who exhibit resistance to conventional DMARDs. The effect, independent of steroid administration is seen despite the variability in the dosage of the drug.

Drugs aimed at suppressing inflammation-provoking cytokines--specifically those linked to T-cells--have improved the treatment of rheumatoid arthritis (RA). Still, the frequency of remission achieved by these biologic agents remains below 50 percent. To increase the success rate of biologic therapy for RA patients, researchers have honed in on a new target: the B cell.

Rituximab, a biologic agent that selectively depletes B cells, has been successfully used to treat non-Hodgkin's lymphoma. It has also been shown to improve disease symptoms for RA patients, when injected at aggressive levels for a two-week period. To investigate this biologic's potential long-term therapeutic value, an international team of scientists set out to compare the effectiveness and safety of different rituximab doses over a 24-week period, with and without steroids. Their study focused on 465 RA patients with moderate to severe symptoms resistant to disease-modifying antirheumatic drugs (DMARDs), including other biologics. The results, featured in the May 2006 issue of Arthritis & Rheumatism.

Drawn from outpatient populations in California, Texas, Arizona, Switzerland, Sweden, Poland, and England, the subjects were randomly divided into nine treatment groups. Three groups received a 1,000-mg. dose of rituximab--two infusions two weeks apart--with either intravenous steroid, oral steroid, or placebo. Three groups received a 50
'"/>




Page: 1 2 3

Related medicine news :

1. Smallpox as Biological Weapons?
2. Biologicals Transfer Proposal between US and Indian Biotechnology
3. Novel Biological Pacemaker Under Construction for Weak Hearts
4. Biologically Women Are More Vulnerable To HIV Infection
5. Biological Clock Could Be Re-Set: Study
6. Gold Nanoparticles Are Good Detectors Biological Toxins
7. Sunglasses Can Really Pull a Fast One on the Biological Clock, and Set a Lag in the Build Up Of Jet Lag
8. Can Men Gauge Biological Paternity Accurately
9. Biological Basis for Homosexuality
10. Biological Basis Behind a Couch Potato
11. Artificial Light May Damage Biological Clock In Premature Babies
Post Your Comments:
(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
Breaking Medicine News(10 mins):Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2
...ck bowel; warnings not mandated on packages, study...ws) -- Parents need to be better warned about pote...wing toys with magnets before shopping for present...gestive tract, the need for surgery, and even deat...
...rescription Prenatal Vitamins , , PrimaCare O...ensive once-daily prescription prenatal vitamin in...nd EPA , , ST. LOUIS, Dec. 17 KV Pharmaceuti...al vitamins - has enhanced the formulation of one ...
...od of use to treat mildly infected diabetic foot u... double-blinded multi-center clinical trials of pe...ARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) an...ild diabetic foot infection were published in the ...
...swire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ... the global life sciences markets, today reported ...ear-end results for the period ended October 31, 2...Services goodwill that was previously announced on...
...SynCare, LLC, today announced that,Ian Duncan has ...-renowned,author and expert in the field of diseas...ings a wealth of experience and knowledge to the S..."Ian is a pioneer in the use of,risk-adjustment an...
... mPay Gateway, a Minneapolis, MN company specia... today that a Minneapolis-area primary care clinic...ceivable by more than 50% after successfully imple...amatic A/R reduction within 12 weeks. , ...
Other Medicine News:Health News:Magnets in Kids' Toys Pose Broad Dangers 2Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 2Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 3Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 4Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 5Health News:Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID 2Health News:Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID 3Health News:Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID 4Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 2Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 3Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 4Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 5Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 6Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 7Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 8Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 9Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 10Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 11Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 12Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 13Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 14Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 15Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 16Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 17Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 18Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 19Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 20Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 21Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 22Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 23Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 24Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 25Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 26Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 27Health News:MDS Reports Preliminary Fourth Quarter 2008 Results 28
(Date:12/4/2009)OMAHA, Neb., Dec. 4 Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services. For nearly 15 years,
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
(Date:12/4/2009)SAN DIEGO, Calif., Dec. 4 Suneva Medical, a privately-held aesthetic medical device company, today announced the appointment of Philip Ranker as Vice President and Chief Financial Officer. In this r
Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4New technique can help diagnose mesothelioma 55087 1New technique can help diagnose mesothelioma 55087 2Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 1Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 2Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 3Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 4Fragile period of childhood brain development could underlie epilepsy 55082 1Fragile period of childhood brain development could underlie epilepsy 55082 2
...Utilized as an Adjuvant and Play Key Role in the,T...., March 20, 2007 /PRNewswire-FirstCall/ --,Immune...,BioSciences Holdings, Inc. , announced today that...nalog, Homspera, suggests that the,compound has po...,adjuvant. Studies performed in animal models of i...
...ronger FDA says drug review programs need more,mon...ire/ -- A new,estimate by the Alzheimer,s Associat...e living with Alzheimer,s disease -- a 10,percent ...ould more,than triple in the coming decades unless...bilitating illness. , The new numbers re-emphasize...
Other Medicine Technology:ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 2ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 3ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 4Alzheimer's Growth Shows Need for Increased FDA Funding 2Alzheimer's Growth Shows Need for Increased FDA Funding 3
Sapphire Surgical Knife With Titanium Handle
Capsule polisher aka Drysdale Nucleus Manipulator
Capsule polisher
Nucleus Spatula & Knife
Medicine Products: